(Q33380414)

English

A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Nizar M Tannir

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Peter F Thall

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Chaan S Ng

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Xuemei Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Leiko Wooten

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Arlene Siefker-Radtke

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Paul Mathew

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lance Pagliaro

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christopher Wood

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Eric Jonasch

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

17 July 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Journal of Urology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

180

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

867-72; discussion 872

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167838

14 July 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167838

14 July 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167838

14 July 2018

Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167838

14 July 2018

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167838

14 July 2018

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167838

14 July 2018

Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167838

14 July 2018

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167838

14 July 2018

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167838

14 July 2018

Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167838

14 July 2018

Monitoring event times in early phase clinical trials: some practical issues.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167838

31 October 2018

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167838

31 October 2018

Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167838

31 October 2018

Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167838

31 October 2018

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18635226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine: a phase II study in patients with advanced renal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18635226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008

1 reference

https://pubmed.ncbi.nlm.nih.gov/18635226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18635226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.JURO.2008.05.017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33380414&oldid=1617317205"